Recently the Danish Competition Appeals Tribunal upheld the Danish CD Pharma-case concerning the drug Syntocinon given to pregnant women during childbirth. This article explains the content of the case and the reasons why it was prioritised by the The Danish Competition Council (the DCC).
Excessive Pricing in Pharmaceutical Markets
Intervention against possible exploitative and excessive prices should always be considered carefully. However, the dynamics of pharmaceutical markets makes it particularly relevant for competition authorities to prioritise cases on unfair prices
Oprettet: 28. februar 2019